依那西普治疗幼年脊柱关节病相关髋关节病变54例

Clinical Efficacy and Nursing of Etanercept for Treating 54 Cases of Juvenile Spondyloarthropathies Related Coxarthropathy

目的观察依那西普治疗幼年脊柱关节病相关髋关节病变的临床疗效及总结护理体会。方法将收治的幼年脊柱关节病相关髋关节病变患儿54例采用依那西普治疗,比较治疗前后髋关节功能及相关实验室指标,并针对治疗过程实施护理。结果治疗12周后,患者的Harris髋关节评分为(89.23±6.81)分,明显高于治疗前的(46.89±6.52)分(t=5.14,P<0.05);患者治疗12周后红细胞沉降率(ESR)、C反应蛋白(CRP)及类风湿因子(RF)等实验室指标均较治疗前明显改善(t=3.62,3.05,6.98,P<0.05)。出现1例胃肠道不适,1例肌酐轻度升高,无其他明显不良反应。结论依那西普治疗幼年脊柱关节病相关髋关节病变具有良好的疗效和安全性,在使用过程中应加强用药观察及不良反应的处理。

Objective To observe the clinical effect of etanercept in treating juvenile spondyloarthropathies related coxarthropathy and the nursing experience. Methods 54 children patients with juvenile spondyloarthropathies related coxarthropathy were treated by the etan-ercept therapy. The hip joint function and the related laboratory indexes were compared between before and after treatment and the nursing aiming at the treatment process was implemented. Results The Harris hip score at 12 weeks after treatment was （89. 23 ＆#177; 6. 81） points, which was significantly increased than （46. 89 ＆#177; 6. 52） points before treatment（ t = 5. 14, P ﹤ 0. 05） . The laboratory indexes of erythrocyte sedimentation rate（ESR）, C - reactive protein（CRP） and rheumatoid factor（RF） after 12 - week treatment were significantly improved compared with before treatment（ t = 3. 62, 3. 05, 6. 98, P ﹤ 0. 05）. 1 cases of gastrointestinal discomfort occurred in this group of patients, creatinine was increased slightly in 1 cases, no other obvious adverse reactions occurred. Conclusion Etanercept has good effi-cacy and safety for treating juvenile spondyloarthropathies related coxarthropathy, the medication observation and the treatment of adverse reactions should be strengthened during the drug using process.